Organization · Venture Capital
LongRiver Investments
LongRiver Investments is a venture capital firm based in Hong Kong, focusing on healthcare, technology, and deep tech sectors. Founded in 2022, it aims to identify and nurture promising companies globally.
Overview
What LongRiver Investments does
What LongRiver Investments is
LongRiver Investments is a venture capital firm based in Hong Kong, focusing on healthcare, technology, and deep tech sectors. Founded in 2022, it aims to identify and nurture promising companies globally.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2022
- Approximate age
- About 4 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find LongRiver Investments elsewhere
Open the official website or a supported primary organization account.
Capability profile
LongRiver Investments as a funder
Investment thesis
LongRiver's thesis is to back future sector leaders in healthcare and technology using global capital, domain expertise, and cross-border networks.
Focus narrative
LongRiver Investments targets a small number of businesses capable of compounding over time, primarily serving Professional Investors as defined under the Securities and Futures Ordinance in Hong Kong. The firm is active in venture capital and private equity, focusing on healthcare, technology, deep tech, and biotechnology.
Value beyond capital
LongRiver Investments adds value to its portfolio companies through its global resources, domain expertise, and cross-border business-development capabilities. The firm emphasizes collaboration with industry leaders and key opinion leaders, supporting companies throughout the full investment cycle from sourcing to exit.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- Greater China · Apac · United States · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Ouro Medicines
Portfolio context
Ouro Medicines: A clinical-stage biotechnology company developing T cell engager therapies for autoimmune diseases, with a planned acquisition by Gilead Sciences. PalmApp: An investment made in April 2026. OpenJobs AI: A March 2026 seed investment alongside Fengshion Capital. Flowith: A March 2026 seed investment alongside HongShan. Rona Therapeutics: Listed as a portfolio company. Neurona Therapeutics: Listed as a portfolio company.
Common questions
What to know about LongRiver Investments
Upseed classifies LongRiver Investments under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.